HONG KONG –LG Chem Ltd. recently received marketing approval for Eucept, its etanercept biosimilar, from South Korea's Ministry of Food and Drug Safety. Based on Amgen Inc. and Pfizer Inc.'s blockbuster biologic, Enbrel, the approval for Eucept is significant for LG Chem, marking the first monoclonal antibody it has developed.
HONG KONG –With a new deal with Ferring Holdings Ltd. to option its innovative microbiome-focused technology, Israel's Mybiotics Pharma Ltd. is looking to expand its market and develop new products. Its second option agreement with Ferring is based on validation of Mybiotics' microbiome-based therapeutic technology focused on women's health.
SINGAPORE – From faster approval processes and shifts in manufacturing processes to changing stakeholder roles and the rise of preventive med tech, discussions at the recent Phar-East 2018 meeting underscored the major currents of change flowing through Asia's biotech and med-tech industries.
SINGAPORE – From faster approval processes and shifts in manufacturing processes to changing stakeholder roles and the rise of preventive med tech, discussions at the recent Phar-East 2018 meeting underscored the major currents of change flowing through Asia's biotech and med-tech industries.
SINGAPORE – China, India, Japan and Korea are prominent Asian players in the global biotech space, while Singapore has emerged as an increasingly notable global contributor, but there remains a gap in terms of contributions from other parts of Southeast Asia. A common theme emerging this week at the Phar-East Pharma and Biotech Festival (formerly known as the BioPharma Asia Convention) focused on ways to foster biotech and bioentrepreneurship in the region.
HONG KONG – Singapore's Tessa Therapeutics Pte. Ltd. is more than halfway through the recruitment for what it said is the world's largest phase III T-cell immunotherapy trial for any cancer indication. If all goes well, the company is expecting a product launch in two years.
HONG KONG – Singapore's Tessa Therapeutics Pte. Ltd. is more than halfway through the recruitment for what it said is the world's largest phase III T-cell immunotherapy trial for any cancer indication. If all goes well, the company is expecting a product launch in two years.
